the elderly, strict vegetarians (i.e., vegan), and patients with malabsorption problems are more likely to become deficient
Certain medical conditions and surgeries can hinder the bodys ability to produce it, leading to an increased risk of vitamin B12 deficiency
Not all formulations contain enough B12 to fully offset absorption losses, especially at higher semaglutide doses
Preclinical research evidence Animal Experiments Obese mouse model: After subcutaneous injection of AOD 9604 (250 g/kg) daily for 8 weeks, the body weight of obese mice decreased by 12%, the subcutaneous fat mass decreased by 25%, and the weight of epididymal adipose tissue decreased significantly
AHK-Cu has been studied in this context for its possible contribution to enhancing VEGF signaling, which may in turn support fibroblast and endothelial cell activity
In clinical trials of Wegovy (FDA-approved semaglutide), participants achieved an average weight loss of approximately 15% over 68 weeks, with some participants achieving up to 20% with continued treatment and adherence, when combined with diet and exercise